Interleukin (IL) 10 is a recently discovered cytokine, originally isolated from T -helper 2 (Th2) cells, which inhibits cytokine production ofT-helper 1 (Thl) cells. Because Thl cells appear to be of importance during the contact hypersensitivity reaction (CHS) we hypothesized that IL-l0 might modulate the outcome of CHS ill vivo. Intraperitoneal injection of murine recombinant IL-l0 (1000 ng) into naive mice 24, 72, or 120 h before sensitization by epicutaneous application of 2,4-dinitrofluorobenzene (ONFB) did not affect ear swelling when ears were challenged 5 d later. However, intraperitoneal injection of IL-l 0 into already sensitized mice 24 h before challenge resulted in a significant suppression of the ear swelling response, suggesting that under the conditions employed IL-l0 is able to block the effector phase, but not the induction phase of CHS ill vivo. The suppression could be reversed by the concurrent injection of an IL-l0 antibody. Moreover, heat inactivation of native IL-10 re-T he molecular mechanisms modulating the cellular interactions in contact allergic reactions are still poorly understood. However, there is strong evidence that the cytokine network and the interplay of accessory signals are part of this complex reaction. In particular, the involvement of cytokines offers promising aspects with regard to pharmacologic intervention and therapeutic options including the application of downregulating cytokines or cytokine antagonists. This is of major relevance because contact dermatitis is a quite freq uently observed disease and can, particularly in the chronic stage, be a disabling disorder.
Interleukin (IL) 10 is a recently discovered cytokine, originally isolated from T -helper 2 (Th2) cells, which inhibits cytokine production ofT-helper 1 (Thl) cells. Because Thl cells appear to be of importance during the contact hypersensitivity reaction (CHS) we hypothesized that IL-l0 might modulate the outcome of CHS ill vivo. Intraperitoneal injection of murine recombinant IL-l0 (1000 ng) into naive mice 24, 72, or 120 h before sensitization by epicutaneous application of 2,4-dinitrofluorobenzene (ONFB) did not affect ear swelling when ears were challenged 5 d later. However, intraperitoneal injection of IL-l 0 into already sensitized mice 24 h before challenge resulted in a significant suppression of the ear swelling response, suggesting that under the conditions employed IL-l0 is able to block the effector phase, but not the induction phase of CHS ill vivo. The suppression could be reversed by the concurrent injection of an IL-l0 antibody. Moreover, heat inactivation of native IL-10 re-suIted in loss of the inhibitory capacity. When mice were sensitized by subcutaneous injection of trinitrophenyl-coupled spleen cells (OTH) instead of epicutaneous application of the hapten (CHS), intraperitoneally-injected IL-l0 suppressed the effector phase, but also the induction phase of DTH. IL-10 did not inhibit the toxic ear-swelling response induced by topical application of two irritants tested (croton oil or benzalkonium chloride) . The capacity ofIL-10 to suppress the effector phase of CHS and OTH supports an important role for this cytokine in the downregulation of type IV immune reactions ill vivo. The finding that IL-l 0 suppresses the induction ofOTH, bqt not of CHS, further suggests that CHS and OTH are related but distinct immune reactions.
Key words: illterleukil1-10/contact hypersetlsitivity/delayedtype hyper5etl5itivity /5 upp ressio 11. ] Illvest Dermatol 103:211- 216, 1994 IL-I0 acts as a mast cell [5] and T-cell growth factor [6] , and enhances B-cell viability and major histocompatibility complex class II expression on B cells [7] . IL-tO also suppresses the release by monocytes/macrophages of a variety of inflammatory mediators including IL-1, IL-6, IL-8, granulocyte/macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and tumor necrosis factor-a (TNF-a) [8, 9] . These biologic abilities strongly suggest an important role for IL-10 in the downregulation of inflammatory and immune reactions, and support its possible clinical use as an immunosuppressor and antiinflammatory agent [9] .
In view of the critical role that Thl cells play during CHS we investigated the role ofIL-10 during this reaction [1] . Our approach was to determine whether contact allergic reactions can be modulated in vivo by injection ofIL-10 at the time of hapten sensitization or hapten challenge. Our results indicate that IL-10 can inhibit CHS i" vivo.
MATERIALS AND METHODS
Mice Balb/c and C3H/HeN mice between 8 and 12 weeks old were purchased from the Versuchstierzuchtanstalt, Hannover, Germany.
Contact Hypersensitivity Mice were sensitized by painting 25 III of 2,4-dinitro-fluorobenzene (DNFB; Sigma Corp., St. Louis, MO) solution (acetone: olive oil, 4: 1) on the shaved abdomen on day 1 and day 2, as reported previously (10) . On day 6 the left ear was challenged by applying 20 III 0.3% DNFB, and the right ear was treated with acetone/olive oil alone. The degree of ear swelling was measured with a spring-loaded micrometer (Mitutoyo, Japan) 24 h after challenge. Contact hypersensitivity 0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatolo gy, Inc. 211 was determined as the amou nt of swelling of the hapten-challenged left ear compared to the thickness of the vehicle (acetone: olive oil)-treated right ear in sensitized anjmals and expressed in cm X 10-3 (mean ± SO). Mice that were ear chaJlenged without prior sensitization served as negative controls. Each treatment group consisted of at least seven animals, and each experiment was performed at least three times.
Delayed Type Hypersensitivity Spleens were removed aseptically from naive donor mice (C3H/HeN) and teased apart in Hanks' balanced saline so lution (HBSS). The suspensions were filtered through .nylon gauze to remove clumps and washed, red blood cells were lysed with Tns-NH.CI solution for 2 min, refiltered, and washed twice with HBSS. Cells were co njugated with trinitrophenyl by incubating them for 15 min at 37 · C in 10 mM recrystallized trinitrobenzene sulfonate in HBSS at pH 7.0. After incubation, the cells were washed three times to remove unconjugated hapten. For se nsitization,S X 10' trinitrophenyl-coupled spleen cells (TNP-SC) were injected subcutaneously at two sites on the dorsal side of the micc. C hall enge was performed after 7 d by injecting 2 X 10 7 TNP-SC (suspended in 40 JlI) subcutaneously into the left footI:'ad. The respective cont~ol groups consisted of nuce that were either senslt1zed or chal lenged With uncouplcd spleen cel ls. Footpad swellin g was measured with a spring-loaded micrometer 24 h after challenge. Oelayed type hypersensitivity was determined as the amount of swelling of the hapten-challenged left footpad compared to the thickness of the unneated right footpad in sensitized mice and expressed in cm X 10-3 (mean ± SO).
Irritant Dermatitis For induction of irritant dermatitis 20
Jll of 1 % croton oil (Serva, Heidelberg, Germany) dissolved in acetone were applied on the left ear [11 J. Ear swelling was measured 8 h after irritant application with a spring-loaded micrometer. Irritant reaction was determined as the amount of swe lling of the irritant-treated left ear compared to the vehicle (acetone)treated right ear and expressed in cm X 10-3 (mean ± SO). In some experiments, a 5% solution of benzalkonium chloride (Sigma Corp .) in acetone was used to elicit irritant dermatitis. Application and measurement was perform ed identicall y as with croton oi l. IL-10 Treatment In Vivo Recombinant mouse IL-10 was expressed iu Eschericilia coli [12] and renatured and purified using ion exchan ge and hydrophobic interaction chromatography [13] . Mice were injected intra peri toneally with IL-10 diluted in sterile endotoxin-free saline in a total volume of "100 JlI at the times indicated in eac h cxperiment. Control mice were treated intraperitoneally with equal volumes of saline, which had no effect on the outcome of both the sensitization and challenge procedure. Likewise, intraperitoneal injection of IL-10 into naive mice did not affect ea. r thickness by itself. Heat inactivation ofIL-l0 was performed by heating at 90·C for 30 min. Biologic activity of IL-l 0 was monitored using the thymocyte proliferation assay as described previously [14] . Neutralizing antibody cxperiments utilized a rat monoclonal immunoglobulin (lg)Gl antibody directed against murine IL-1 0 (UBI Company, Lake Placid, NY) or an isotype control (rat IgG l , The Binding Site Inc., Birmingham, U.K.) .
Thymocyte Proliferation Assay Thymocytes obtained from 7-weekold Balblc mice (1 X 10 5 per well) were cultured in flat-bottom 96-well pl ates with IL-l 0 (native or heat inactivated) at various conce ntrations in the presence of IL-2 (500 U/ml) and IL-4 (250 U/mJ) in 300 Jll of RPMl medium (Gibeo, Gaithersburg, MO) supplemented by L-glutamine (200 mM) , modified Eagle's medium (MEM) amino acids, MEM vitamins, sodium bicarbonate, penicillinelstreptomycin (Sigma), 5 X 10-5 M 2-mercaptoethanol, and 10% fetal bovine serum (Gibeo) for 4 d [14J. The wclls were then pulsed with 1 JlCi/well [3H]thymidinc and harvested 18 h later. Activity is expressed as cpm (mean of triplicates).
Histology The ears were fi xed in buffered formaldehyde, embedded in paraffin, sectioned, and stained with hematoxylineosin.
Statistical Analysis The statistical significance of differences in the means for each experimental group was calculated with the Student t test.
Mean differences were considered significant when p < 0.05.
RESULTS
Effect of IL-l0 on the Induction of CHS To eval uate the effect of IL-IO on the induction phase of CHS, groups of Balb/c mice were injected intraperitoneally with varying amounts of murine IL-I0 in 100 J.lI saline 24 h before epicutaneous sensitization with DNFB. In three independent experiments of this type, IL-10 did not alter the outcome of CHS response upon ear challenge 6 d later ( Fig 1A) . Because suppression of the induction of CHS has been observed upon injection of supernatants obtained from UVirradiated murine keratinocytes 120 h before sensitization [ 1,000 20.6 ± 0.9 cm X 10-3 (B). Negative controls consist of unsensitized mice that wcre ear challen ged only. Experiments were repeated at least three times; results show one representative experiment. n.s., not significantly different from positive control. kinetic analysis was performed by injecting 1000 ng IL-10 24, 72, or 120 h before hapten application. However, induction of CHS was not affected under any of these conditions ( Fig 1B) .
Administration ofIL-l0 Results in Suppression of the Effector Phase of CHS DNFB-sensitized Balb/c mice received 1-2000 ng ofIL-10 i.p. 24 h before hapten challenge on the ears. In each of five experiments, a statistically significant reduction in ear swelling compared with control animals was observed upon injection of 1000 ng or more (Fig 2A) . Interestingly, there was no real dose-dependent effect because it was not possible to show an increase of suppression by increasing the amo unts of IL-I0 ir~jected.
Optimal reduction of CHS was seen when 1000 ng was administered 24 h before challenge ( Fig 2B) ; injection of IL-10 less than 12 h before challenge did not affect ear swelling. Application of DNFB to the ears of sensitized mice caused both epidermal and dermal alterations, in particular, spongiosis, edema, hemorrhage, and leukocyte infiltration ( Fig 3A) . Administration of IL-10 24 h before elicitation inhibited both the dermal and epidermal component of the CHS reaction ( Fig 3B) . The inhibitory effect ofIL-l0 on the elicitation of CHS was not strain specific, because similar data were obtained with C3H/HeN mice (Table I) . To prove that the inhibition of the elicitation was indeed mediated by IL-l 0, a neutralizing anti -IL-l 0 antibody was used. Concurrent injection of the antibody (50.ug) blocked the IL-I0-mediated suppression of the effector phase of CHS. In contrast, application of the isotype did not affect the inhibitory activity of IL-I0 (data not shown). As a further control, the anti-IL-I0 antibody was administered in the absence oflL-l O. Although there was some variation in the ear thickness of challenged mice compared to positive control animals the differences were not statistically significant (Table I) .
To further confirm the specifity of the inhibitory effect of IL-l 0 on the effector phase of CHS, heat-inactivated IL-I0 was used. Immediately prior to injection, IL-lO was heat inactivated at 90°C for 30 min. The efficacy of this treatment was monitored with the thymocyte proliferation assay demonstrating that native IL-10 induces proliferation of thymocytes in a dose-dependent manner, whereas heat-treated IL-l 0 did not exhibit any biologic activity ( Fig  4) . Heat-inactivated IL-I0 injected intraperitoneally into sensitized mice 24 h before ear challenge failed to suppress the effector phase SUPPRESSION OF CONTACT HYPERSENSITIVITY BY IL-IO 213 ofCHS in Balb/c mice, in contrast to native IL-IO, which blocked it significantly (Table II) .
Effect of IL-l0 on Irritant Reaction To investigate whether IL-I0 also suppresses irritant reactions, IL-I0 w as injected intraperitoneally into Balb/c mice 3 or 24 h before application of 1 % croton oil on the left ear. Toxic ear swelling, however, was not affected significantly in mice pretreated with IL-I0 when compared with control animals (treated with irritant only) (Table III) . Similar results were obtained when benzalkonium ch loride was used as an irritant (Table III) .
Administration ofIL-l0 Suppresses both Induction and Elicitation Phase of DTH Although CHS and OTH are both T -cell-mediated immune reactions with delayed onset it recently has been shown that both reactions induced and elicited by epicutaneous application of hapten and injection of hapten-conjugated cells, respectively, are not equivalent and interchangeable [15J . Therefore, the effect of IL-IO on OTH induced by TNP-SC was studied. We first investigated whether IL-I0 has an effect on the induction ofOTH. For this purpose, C3H/HeN mice were injected intraperitoneally with 1000 ng IL-IO 24 h before sensitization by subcutaneous application of TNP-SC. Seven days later the mice were challenged by injecting TNP-SC into the footpads of sensitized or control mice. In contrast to the findings with CHS, injection ofIL-IO 24 h before sensitization significantly suppressed the induction of OTH w hen compared with the positive controls (normal immunized animals) (Table IV showing To address the effect of IL-I0 on the elicitation phase of DTH, IL-I0 was injected intraperitoneally 24 h before subcutaneous challenge into mice that were already sensitized by subcutaneous injection ofTNP-SC. In each of three experiments a statistically significant reduction in footpad swelling was observed (Table IV showing one representative experiment). These data indicate that IL-lO is able to suppress the elicitation phase of CHS and DTH. However, IL-I0 downregulated only the induction phase of DTH, but not of CHS, suggesting that different mechanisms control the modulation of these responses.
DISCUSSION
A number of studies are available addressing the immunomodulatory effects ofIL-I0 in vitro. They provide good evidence that IL-10 inhibits antigen presentation [3, 4] and secretion of cytokines by macrophages [8, 9] ; recent data also show that IL-I0 can affect T cells directly [6, 16] . However, only a few reports exist addressing the itl vivo effects of IL-l 0 in T -cell-mediated reactions. Most of these studies addressed the function of IL-I0 in mouse models of parasitic infections [17] . They have shown that IL-10 is released in the course of certain parasitic infections and that it suppresses macrophage effector function and the release of interferon-y [18 ,19] . In cpm x 1,000
7------ a recent report by Powrie et at [20] , IL-I0 was shown to inhibit the elicitation of 48-h footpad DTH response to Leishmanial antigen in mice previously injected with Leishmania. Because Th 1 cells mediate protective immunity in these experimental systems the data suggest a regulatory role of IL-l 0 in the mediation of susceptibility and immunity to these infections. Our own experiments aimed to investigate the it! vivo effects of IL-I0 in CHS, another T-cellmediated reaction. We expected that IL-lO will be ab le to block the induction of CHS due to the inhibitory activity on antigen presentation [3, 4] . However, intraperitoneal injection of murine recombinant IL-IO at various concentrations did not affect the outcome of CHS significantly. Sensitization was not affected when IL-10 was applied either 24, 72, or 120 h before epicutaneous hapten application.
In contrast, induction of DTH could be effectively blocked by intraperitoneal administration of 1000 ng IL-10 24 h before sensitization by subcutaneous injection of TNP-SC. Both CHS and DTH are T-cell-mediated immune reactions and because of many similarities between CHS and DTH, they previously have been used interchangeably [15 ,21-23] . Accordingly, it has been assumed that they are suppressed by the same mechanism following irradiation with ultraviolet (UV)B light. Recently, however, major differences between these reactions became evident: although UVBirradiated mice could be immunized effectively for DTH by a subcutaneous injection of TNP-SC derived from normal mice, this procedure did not restore the CHS reaction measured by painting TNCB of the ears [15] . Moreover, treatment of UVB-irradiated mice with methylprednisolone before immunization prevented the suppression of DTH, but had no effect on the suppression of CHS [15] . Thus, our findings , i.e ., that IL-10 prevents induction ofDTH but not of CHS, further support the hypothesis that DTH and CHS are based upon distinct mechanisms in which different pathways seem to be involved. However, we cannot exclude that by changing the experimental conditions, e.g., application of even hi gher doses, multiple injections, or selection of other timepoints of injection, IL-I0 will be able to suppress the induction of CHS ill rlivo. The present data, however, are in agreement with a recent observation by Rivas and Ulrich. Using the UVB model they could show that injection of an anti-IL-I0 antibody prevents UVB-induced suppression of the induction of DTH [24] but not of CHS. t These data yield indirect evidence that IL-I0 is involved in the suppression of the induction of DTH, but not of CHS. Conversely, Rivas and Ulrich could demonstrate that application of TNF-a antibodies t Rivas JM, Ullrich SE: Essential role of keratinoeyte-dcrivcd interleukin-IO in the UV-induced suppression of delayed type hypersensitiviry but not contact hypersensitiviry (abstr.)] [livest D ermatoi100:S22A, 1993. • Hapten was applied o n the razor shaved abdo m en on days I and 2 .
• Hapten was app lied on the left ear on day 6. . . . , N ative o r inactivated IL-IO (1000 ng) was lI1Jectcd mtrapentoncally 24 h before performance of challen ge. d c m X 10-'. , Significantly different from positive control (p < 0.001).
f Nor significantl y ddTerent fro m posltlve control. reve rses UVB-induced suppression of the induction of CHS, but not ofDTH.·' Interestingly, we found that IL-10 injected intraperitoneally was able to suppress the elicitation of both CHS and DTH. The inhibitory effect of IL-l 0 on the effector phase is speci fi c beca use it could be blocked by concurrent injection of an anti -IL-l 0 antibody. In several control experiments iruection of the IL-I0 antibody alone affected ear swellin g somewhat, but these changes were never significant. These va ri ations may reflect neutraliza tion of endoge nous IL-I0. On the other hand, mice treated continuously from birth until 8 weeks of age with anti -IL-l 0 antibody appeared to be healthy and, by numerous parameters, unaffected by the treatment [25, 26] . To furth er prove the specificity, IL-I0 was inactivated by heat treatment. Incubation at 90 ·C for 30 min res ulted in a complete loss of bioactivity, as checked in the thymocyte proliferation assay [14] . As expected, injection of heat-inactivated IL-I0 had no effect on the el icitation of CHS.
CHS-induced ear swelling was blocked significantl y by injection of at least 1000 ng ofIL-l O. Although lower doses had some inhibitory activity, the effects were not significant. Moreover, there was no real dose-dependent effect beca use it was not possible to increase the inhibitory activity by increasing the amounts of IL-I0. This may suggest that in this complex ill vivo system probably other mediators are indirectly involved. To be inhibitory, IL-I0 had to be administered at least 12 h before hapten challenge; maximum suppression was observed upon injection 24 h before challenge. The need of this relatively long period suggests that the observed effect ofIL-10 is not a direct one, but could be mediated indirectl y, e.g. , via other cytokines. In this respect, TNF-O' appears to be of primary interest because it recentl y has been identified as a critical mediator in hapten-induced irritant and contact hypersensitivity reactions [27] . In particular, injection of anti -TNF-O' antibodies into sensitized mice before application of the challenging dose of the respective hapten abrogated the ear-swelling response significantly. Accordingly, we recently found that pentoxifylline, a phosphodiesterase inhibitor known to inhibit th e release of TNF-O', is • Difference of th e thickness of the irritated left car minus th e thickness of the veh icle-treared right car (cm X 10-').
• IL-l 0 (1000 n g) was injected intraperitoneally 3 h before irrita nt application.
, IL-I0 (1000 ng) was injected intraperitoncall y 24 h before irritant application. I 1 % croron oi l was applied on the le ft ear. , Not significant compared to positi ve control (irritation onl y).
1 5% benzalkonium chl oride was applied on tlte left year.
ab le to inhibit ear chall enge in sensitized mice [11] . Moreover, it was observed that pentoxifylline also reduces irritant dermatitis, as was the case by injection of anti -TNF-O' antibody, suggesting that TNF-O' is also of importance in the m ediation of irritant reactions [27] . IL-lO effici entl y blocks the ill Ilitro production ofTNF-O', as well as of other cytokines, by lipopolysaccharide-activated monocytes/macrophages [8] . Through this mechanism IL-l 0 may be able to prevent lethality in experimental endotoxemia [13, 28] . To further elucidate w hether the inhibitory effect ofIL-I0 on the effector phase of CHS could be due to the inhibition of the release ofTNF-0', the effect of IL-IO on irritant dermatitis, another TNF-O'mediated reaction, was studied. However, in contrast to pentoxifylline and anti -TNF-O' antibody, IL-I0 was not able to reduce toxic ear swelling response elicited by topical application of croton oil and benzalkonium chloride, respectively. Although these data do not definitely prove it, they favor the view that inhibition of TNF-O' may not be the primary mechanism by which IL-IO prevents the effector phase of CHS. M ore likely, IL-IO may exert its inhibitory effe cts on CHS and OTH Ilia modulation of antige n-presenting cells. In a variety of antigen-driven secondary reactions IL-lO has been found to be inhibitory, acti ng primarily on antigen-presenting cells. It was shown that IL-I0 inhibits the ability of macrophages, but not B celis, to induce interferon-y secretion from Th 1 cells [3 ,4] . However, IL-I0 has no effect on the capacity of dendritic cell s to stimulate proliferation of C04+ or C08+ T cells from unprimed mice, although macrophage-driven proliferation is inhibited [29] , a finding in accordance with data using a mitogen-driven system [30] . The effector phase of CHS and OTH reflects a primed (secondary) i/1 "iva system. Therefore, the inhibitory activity ofIL-l 0 on the elicitation of CHS and OTH co uld be explained by the effects of IL-lO on antigen-presenting cell s, as deITlOl1strated in the ill vitro system [31] . On the other hand, there is recent evidence, at least in the human system, that IL-IO exerts direct downregul atory effects also on T cells [16] . In particular, it was reported that IL-10 directly inhibits IL-2 production and proliferation of activated human subsets of C04+ T-cell clones and T cell s isolated from peripheral blood [1 6 ]. In ad dition, IL-IO cou ld indirectly affect eith er antigen-presenting cells or T cells by modul ating the release of other cytokines, which could explain the relatively lon g period IL-I0 has to be injected to block CHS and DTH. Weare currently investigating whether IL-lOin our in villo models of C HS and OTH primarily affects antigenpresenting cells, T -effecto r cel ls, or both.
In summary, the present study demonstrates a new ill villa function ofIL-lO, the abi lity to supp ress induction ofOTH and to block the elicitation of both CHS and OTH. In particular, the latter findings emphasize th e ro le of IL-10 as an immunosuppressive and antiinflammatory drug, giving rise to speculation about pharmacologic intervention in these types of immune reactions by application of IL-IO . Moreover, the observation that IL-I0 suppresses the induction of OTH, but not of CHS, further supports the concept that OTH and CHS are related but distinct immunologic reactions involving different pathways. • IL-IO (1000 ng) was injected intraperitoneally 24 h before sensitization and challenge, respectively. . b Mice were sensitized by subcutaneous injection of TNP-SC or SC (5 X 10 7 cells) at two sites on the dorsal skill. 'Mice were challenged by subcutaneous injection ofTNP-SC or SC (2 X 10 7 cells) into the left footpad .
. . . J Footpad swelling was measured 24 h after challenge and expressed as the difference (cm X 10-', mean ± SO) of the tluckness of the challenged left footpad mlllusthe thIckness of the untreated right footpad .
• p < 0.005 significantl y different from positive control.
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